Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastoma

25 Mar 2021

Abstract excerpt

BACKGROUND: Glioblastoma is the most common primary brain tumor and remains uniformly fatal, highlighting the dire need for developing effective therapeutics. Significant intra- and inter-tumor heterogeneity and inadequate delivery of therapeutics across blood-brain barrier continue to be significant impediments towards developing therapies which can significantly enhance survival. We hypothesize that microRNAs...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular vesicles in disease
Share to Glioma Diagnosis and Treatment
Share to MicroRNA in disease regulation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33765907
DOI: 10.1186/s10020-021-00293-4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Nanocell-mediated delivery of miR-34a counteracts temozolomide resistance in glioblastomaPMID 33765907Read ↗

Therapeutic Targets in Glioblastoma: Molecular Pathways, Emerging Strategies, and Future DirectionsSemantic proximity Read ↗

Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapySemantic proximity Read ↗

Molecular targets in glioblastoma.Semantic proximity Read ↗

Unveiling the Influence of Tumor Microenvironment and Spatial Heterogeneity on Temozolomide Resistance in Glioblastoma Using an Advanced Human In Vitro Model of the Blood‐Brain Barrier and GlioblastomaSemantic proximity Read ↗

A rationally identified panel of microRNAs targets multiple oncogenic pathways to enhance chemotherapeutic effects in glioblastoma modelsSemantic proximity Read ↗

Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastomaSemantic proximity Read ↗

Discovery and therapeutic exploitation of Master Regulatory miRNAs in GlioblastomaSemantic proximity Read ↗

Genome scale CRISPR Cas9a knockout screen reveals genes that controls glioblastoma susceptibility to the alkylating agent temozolomideSemantic proximity Read ↗

Targeting EGFR for Treatment of Glioblastoma: Molecular Basis to Overcome ResistanceSemantic proximity Read ↗

The Role of microRNAs in Multidrug Resistance of GlioblastomaSemantic proximity Read ↗

Gene therapy in glioblastoma multiforme: Can it be a role changer?Semantic proximity Read ↗

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.